Figure 3

Effect of FGF9 on growth and anti-apoptosis of gastric cancer cells. (A) Effect of FGF9 on growth of gastric cancer cells. (B-D) Effect of FGF9 on anti-apoptosis capability of gastric cancer cells. (B) Representative graphs of FACS analysis using Annexin V-FITC staining. AGS cells were treated with FGF9 (10 ng/ml) and evaluated as described in Materials and Methods. (C) Changes in the number of apoptotic AGS and MKN28 cells treated with FGF9. (D) Effect of anti-FGF9 neutralizing antibody (Neu Ab; 1 μg/ml) on FGF9 (10 ng/ml)-induced anti-apoptosis in AGS and MKN28 cells. All the results are expressed as the mean ± SD of four samples. Significantly lower than control: *P <0.05, **P <0.01. Significantly greater than the FGF9-treated group: ^#P <0.05, ^##P <0.01.